HK1006455B - Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds - Google Patents
Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds Download PDFInfo
- Publication number
- HK1006455B HK1006455B HK98105643.3A HK98105643A HK1006455B HK 1006455 B HK1006455 B HK 1006455B HK 98105643 A HK98105643 A HK 98105643A HK 1006455 B HK1006455 B HK 1006455B
- Authority
- HK
- Hong Kong
- Prior art keywords
- methyl
- imino
- bis
- pyrrole
- carbonyl
- Prior art date
Links
Description
The present invention relates to ureido derivatives of substituted pyrroles, to a process for their preparation and to a pharmacological composition containing them.
The pyrrole derivatives of the invention may be regarded as derivatives of Distamycin A which is a known compound having the following formula
Literature referring to Distamycin A includes, for example NATURE 203, 1064 (1964).
The present invention provides ureido derivatives of substituted carboxypyrroles having the following general formula (I)
wherein
each of m and n, being the same, is an integer of 1 to 3; W is oxygen or sulphur;
each of the B groups, which are the same, is
- a) a phenyl or naphthyl group substituted by one or more acid groups;
- b) a saturated or unsaturated, heteromonocyclic or heterobicyclic ring, containing one or more heteroatoms chosen from nitrogen, oxygen and sulphur, substituted by one or more acid groups;
- c) a 2-deoxy-D-glucose group substituted by one or more acid groups; or
- d) a -CH₂(CHA)rCH₂A group, wherein each A group, being the same or different, is an acid group and r is 0, 1 or 2; and wherein each of the above acid groups is independently chosen from sulfonic, sulfuric, sulfamic, sulfinic, phosphoric, phosphonic, phosphamic and carboxylic acid groups; and the pharmaceutically acceptable salts thereof.
When two or more acid groups are present on a B group, as defined above under a), b) and c), they may be the same or different. The acid groups are SO₃H, SO₄H, SO₃NH₂, SO₂H, PO₄H₂, PO₃H₂, PO₃NH₃ or CO₂H groups.
Preferably the B groups, as defined above under a), b) and c), are substituted by 1 to 3 of such acid groups.
When B is a ring as defined above under b) it is for example tetrahydropyranyl or tetrahydrofuranyl.
When B is a group as defined above under d) r is preferably 2.
As already said, the invention includes within its scope also the pharmaceutically acceptable salts of the compounds of formula (I).
Examples of pharmaceutically acceptable salts are either those with inorganic bases, such as sodium, potassium, calcium and aluminium hydroxydes, or with organic bases, such as lysine, arginine, N-methyl-glucamine, triethylamine, triethanolamine, dibenzylamine, methylbenzylamine, di-(2-ethyl-hexyl)-amine, piperidine, N-ethylpiperidine, N,N-diethylaminoethylamine, N-ethylmorpholine, β-phenethylamine, N-benzyl-β-phenethylamine, N-benzyl-N,N-dimethylamine and the other acceptable organic amines.
Preferred compounds according to the present invention are the compounds of formula (I), wherein
each of m and n, being the same, is 2;
W is oxygen;
each of the B groups, which are the same, is a') a phenyl or naphthyl group by 1 to 3 acid groups; b') a tetrahydropyranyl or tetrahydrofuranyl ring substituted by 1 to 3 acid groups; or c') a 2-deoxy-D-glucose group substituted by 1 to 3 acid groups; and the pharmaceutically acceptable salts thereof.
Specific examples of preferred compounds of the invention, are the followings:
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylamino))bis(1,3-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(3,5-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,5-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,4-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,6-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,6-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(3,6-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,5-naphthalendisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis (1-naphthalensulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis (3-naphthalensulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(5- naphthalensulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,3,5-naphthalentrisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,4,6-naphthalentrisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,4,6-naphthalentrisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,3,6-naphthalentrisulfonic acid);
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,3,5-naphthalensulfonic acid);
2,2'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pirrole)carbonylimino))bis(2-deoxy-D-glucose-6-sulphate); and
2,2'(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2-deoxy-D-glucose-6-phosphate);
and the pharmaceutically acceptable salts thereof, in particular the sodium and potassium salts.
The compounds of the invention, and the salts thereof, can be prepared by a process comprising reacting a compound of formula (II)
wherein n and B are as defined above, or a salt thereof, with a compound of formula (III)
wherein W is as defined above, and each of the X groups, which may be the same or different, is a good leaving group, and if desired, salifying a compound of formula (I) thus obtained; and/or if desired, obtaining a free compound of formula (I) from a salt thereof.
The present invention also provides a compound of formula (II), or a salt thereof, with the proviso that B is not a -CH₂(CHA)rCH₂A group as defined above.
A salt of a compound of formula (II) may be a salt with inorganic bases, for example those mentioned above as to the pharmaceutically acceptable salts of the invention, the sodium and potassium salts being the preferred.
Preferred examples of good leaving groups, according to the meaning of X, are halogen atoms, in particular chlorine, or other easily displaceable groups such as, imidazolyl, triazolyl, p-nitrophenoxy or trichlorophenoxy.
The reaction of a compound of formula (II), or a salt thereof, with a compound of formula (III) is an analogy process and can be carried out according to well known methods; for example according to the conditions described in organic chemistry for this kind of reaction, i.e. for synthesis of urea derivatives.
Preferably when in a compound of formula (III) X is an halogen atom, e.g. chlorine, the reaction may be carried out at a molar ratio of compound (II), or a salt thereof: compound (III) from about 1:1 to about 1:4. The reaction is preferably performed in organic solvents such as dimethylsulphoxide, hexamethylphosphotriamide, dimethylacetamide or, preferably, dimethylformamide, or their aqueous mixtures, or in water/dioxane or water/toluene mixtures, in the presence of either an organic base such as triethylamine or diisopropylethylamine, or an inorganic base such as sodium bicarbonate or sodium acetate. The reaction temperature may vary from about -10°C. to about 50°C. and the reaction time from about 1 to about 12 hours.
The compounds of formula (I) prepared according to the above described procedures may be purified by conventional methods such as by silica gel or alumina column chromatography, and/or by rechrystallization from organic solvents such as lower aliphatic alcohols or dimethylformamide.
Analogously salification of a compound of formula (I) can be carried out by known methods in the art.
The compounds of formula (II) may be obtained according to known procedures.
For instance, a compound of formula (II) may be obtained by reduction of a compound of formula (IV)
wherein
n and B are as defined above by methods well known in the art.
The compounds of formula (IV) may be obtained by reacting an amine of formula B-NH₂, where B is defined as above, with a compound of formula (V)
wherein
n and X are as defined above.
Also the reaction of an amine of formula B-NH₂ with a compound of formula (V) is a well known process.
Alternatively a compound of formula (IV) wherein n is 2 or 3 may be obtained by a multi-step-process comprising reacting a compound of formula (VI)
wherein X is as defined above, with an amine of formula B-NH₂, in which B is as defined above. The reaction, which may be carried out according to known methods, provides compounds of formula (VII)
wherein B is as defined above.
A compound of formula (VII) is reduced according to known methods to provide a compound of formula (VIII)
wherein
B is as defined above, wich in its turn is reacted with a compound of formula (VI), as defined above, thus obtaining a compound of formula (IV), as defined above, wherein n is 2.
If a compound of formula (IV), wherein n is 3 is desired, a further reduction and acylation step is required.
The compounds of formula (V) are known compounds and may be obtained for example according to Heterocycles, vol 27,No. 8, 1988, p. 1945-52.
The compounds of formula (VI) and the amine of formula B-NH₂ are known products or may be easily obtained according to known methods.
The compounds of the invention have been found to be active as angiogenesis inhibitors.
By angiogenesis inhibitor is meant an agent capable of suppressing the growth of new blood vessels. Therefore the compounds of the present invention are useful in treating several pathological conditions in mammals, including humans, where the growth of new blood vessels is detrimental, for example in chronic inflammation, diabetic retinopathy, psoriasis, rheumatoid arthritis and tumor growth. In particular, in the cancer therapy the compounds of the invention can be administered alone or in association with antitumor agents such as doxorubicin, etoposide, fluorouracil, mephalan, cyclophosphamide, bleomycin, vinblastin or mitomycin. The angiogenesis inhibitor activity of the compounds of the present invention is shown e.g. by the fact that they have been found to be active in the chorioallantoic membrane test, according to the Folkman's method [Nature, 297, 307 (1982)].
Moreover the compounds of the present invention have been found to be endowed with TNF α-neutralizing activity and therefore they can be employed in humans for prophylactic and/or therapeutic use in any disease state in which TNF α is known to play a detrimental role. Typically such disease states are cachexia, septic shock, graft-versus-host disease, AIDS, cerebral malaria, rheumatoid arthritis.
The TNF α-inhibiting activity of the compounds according to the present invention is proven, for instance, by the fact that they are active in inhibiting the cytotoxic activity of human TNFα on untreated mouse LM cells.
The compounds of the invention can be administered by the usual routes, for example, parenterally, e.g. by intravenous injection or infusion, intramuscularly, subcutaneously, topically or orally.
The dosage depends on the age, weight and conditions of the patient and on the administration route.
For example, a suitable dosage for administration to adult humans may range from about 0.5 to about 300 mg pro dose 1-4 times a day.
The pharmaceutical compositions of the invention may contain a compound of formula (I) as the active substance, in association with one or more pharmaceutically acceptable excipients and/or carrier
The pharmaceutical compositions of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
For instance, solutions for intravenous injection or infusion may contain as carrier, for example, sterile water or preferably, they may be in the form of sterile aqueous isotonic saline solutions.
Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
In the forms for topical application, e.g. creams, lotions or pastes for use in dermatological treatment, the active ingredient may be mixed with conventional oleoginous or emulsifying excipients.
The solid oral forms, e.g. tablets and capsules, may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch and potato starch; lubricants, e.g. silica, talc,stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethyl cellulose, polyvinylpyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates, sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, for instance, lecithin, polysorbates, laurylsulphates: and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in a known manner, for example by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
Furthermore, according to the invention there is provided a method of treating pathological conditions where the growth of new blood vessels is detrimental,for example chronic inflammation, diabetic retinopathy, psoriasis, rheumatoid arthritis and tumors, in mammals in need thereof, including humans, comprising administering to the said mammals a composition of the invention.
Object of the present invention are also products containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a biologically active amount of a different active agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease in which TNFα plays a detrimental role.
The term "combined" method of treatment is meant to include both separate and substantially contemporaneous administration of a composition containing a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing a therapeutically effective amount of a different pharmaceutically active agent.
Active agents, that can be formulated with a compound of the invention or alternatively, can be administered in a combined method of treatment depend on the disease state to be cured and are, for instance, gamma globulin, immune globulin and monoclonal antibody products, antibiotics and antimicrobial products. Typically, the antimicrobial agents may include a penicillin in conjunction with an aminoglycoside (e.g. gentamycin, tobramycin). However several well known additional agents, e.g. cephalosporins, can be utilized.
The following examples illustrate but do not limit the invention.
To a solution of 8-(amino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylmino))(1,5-naphthalendisulfonic acid) disodium salt hydrochloride (0.6 g., 1.02 10⁻³ mols) in water (20 ml), sodium acetate (0.328 g., 4 mmols) was added under stirring. The whole was cooled to 0°C with an ice-salt bath, then a solution of phosgene in toluene (1 ml ∼ 4 eq.) was added dropwise. The mixture was stirred 1 hr at 0°C.
The solvents were evaporated under vacuum and the residue was taken up with methanol and filtered. The filtrate was evaporated and the residue was chromatographed on a silica gel column with methylene chloride: methanol: 60:40 as eluent, affording 0.16 g. of the title compound.
I.R.(KBr) cm⁻¹: 3440 b, 1660, 1640, 1585, 1180, 1030.
N.M.R. (DMSO-d6):δ3.84 (3H,s); 3.85 (3H,s); 6.80 (1H,d); 7.07 (2H,m); 7.41 (2H,m); 7.92 (2H,dd); 8.12 (1H,s); 8.27 (1H,dd); 9.07 (1H,dd); 9.90 (1H,bs); 12.27 (1H,bs).
F.A.B.-M.S.: m/z 1209; M⁺+1; 1231, M⁺+23; 1128, M-80
U.V. (H₂O) nm:
316 (331), 229 (478)
By analogous procedure the following compounds can be obtained:
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrole-carbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(3-naphthalensulfonic-acid)disodium salt.
I.R.(KBr)cm⁻¹: 3430 b, 1640, 1585, 1200, 1030
N.M.R.(DMSO-d6): δ 3.84 (6H,s); 6.86 (1H,d); 7.05 (1H,d); 7.24 (1H,d); 7.35 (1H,d); 7.54 (2H,m); 7.70 (1H,dd); 7.90 (2H,m); 8.15 (1H,d); 8.15 (1H,d); 8.95 (1H,bs); 9.94 (1H,bs); 10.03 (1H,bs).
F.A.B. M.S.: m/z 1005, M⁺+H; 1027, M⁺+Na
U.V. (H₂O)nm:
304 (366), 226 (1002)
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1-naphthalensulfonic acid) disodium salt;
8-8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(5 -naphthalensulfonic acid) disodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,3-naphthalendisulfonic acid) tetrasodium salt;
8-8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(3,5-naphthalendisulfonic acid) tetrasodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,5-naphthalendisulfonic acid) tetrasodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,4-naphthalendisulfonic acid) tetrasodium salt;
8-8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(1,6-naphthalendisulfonic acid) tetrasodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-mehtyl-4,2-pyrrole)carbonylimino))bis(2,6-naphthalendisulfonic acid) tetrasodium salt; and
8-8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(3,6-naphthalendisulfonic acid) tetrasodium salt.
To a solution of 8-(amino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))(1,3,5-naphthalentrisulfonic acid trisodium salt) hydrochloride (2.19 g, 3 mmols) in water (60 ml) and dioxane (15 ml), sodium acetate (0,984 g, 12 mmols) was added under stirring. The whole was cooled to 8°C with an ice bath, then a 20% solution of phosgene in toluene (3 ml, ∼ 6 mmols), diluted with ml 9 of dioxane, was added dropwise in 1 hr.
The mixture was stirred 2 hrs at ∼8°C.
The solvents were evaporated under vacuum and the residue was taken up with methanol.
After filtration of the salts, the filtrate was evaporated and the residue was cromotographed on a silica gel column with methylene chloride: methanol: water 60:40:4 as eluent, affording g 0.82 of the title compound.
I.R.(KBr)cm⁻¹: 3440 b, 1640, 1590, 1190, 1030
N.M.R.(DMSO-d6): δ3.80 (3H,s); 3.83 (3H,s); 6.80 (1H,d); 7.06 (2H,m); 7.40 (1H,d); 7.88 (1H,d); 7.99 (1H,d); 8.02 (1H,bs); 8.57 (1H,d); 9.33 (1H,d); 9.91 (1H,bs); 12.29 (1H,bs).
F.A.B.-M.S: m/z 1411, M⁻-H; 1389, M⁻-Na
U.V. (H₂O)nm:
311 (266), 233 (551).
By analogous procedure the following compounds can be obtained:
8-8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,4,6-naphthalentrisulonic acid) hexasodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,4,6-naphthalentrisulfonic acid) hexasodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,3,6-naphthalentrisulfonic acid) hexasodium salt; and
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,3,5-naphthalentrisulfonic acid) hexasodium salt.
The compound 8-(nitro-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))(1,3,5-naphthalentrisulfonic acid trisodium salt) (2.17 g = 3 mmols) was dissolved into a mixture of water (120 ml) and 1N HCl (3 ml) and reduced over a Pd catalyst (10% on carbon; mg 900) under H₂ pressure (50 p.s.i.) for 3 hours.
The catalyst was filtered and the resulting solution was concentrated in vacuum to dryness, affording 2,1 g of the title compound.
I.R.(KBr) cm⁻¹: 3440 b, 1640, 1520, 1190, 1030
N.M.R.(DMSO-d6): δ 3.85 (3H,s); 3.90 (3H,s); 7.1 (3H,m); 7.4 (1H,d); 7.95 (2H,m); 8.60 (1H,d); 9.35 (1H,d); 10.1 (4H,bs); 12.3 (1H, bs)
To a solution of 8-(amino(N-methyl-4,2-pyrrole)carbonylimino) (1,3,5-naphthalentrisulfonic acid trisodium salt)hydrochloride (1.824 g, 3 mmols) in water (45 ml) and 1N NaOH (1 ml), sodium acetate (0.492 g, 6 mmols) was added under stirring.
The solution was cooled at 5°C with an ice bath, then a solution of (4-nitro-N methyl-2-pyrrole) carbonyl chloride (0.567 g, 3 mmols) in dioxane (30 ml) was added dropwise in 1 hr. The mixture was stirred 1 hr at 5°C, acidified at pH 4 with 1N HCl and evaporated under vacuum to dryness. The residue was treated with ethyl acetate (300 ml), stirred for 1 hour and filtered, to obtain the title compound (2.1 g).
I.R. (KBr) cm⁻¹: 3440 b, 1650, 1520, 1305, 1195, 1030
N.M.R. (DMSO-d6; 80 M.Hz.) δ : 3.89 (3H,s); 3.99 (3H,s); 7.18 (1H,d); 7.46 (1H,d); 7.70 (1H,d); 8.02 (2H,m); 8.2 (1H,d); 8.63 (1H,d); 9.41 (1H,d); 10.45 (1H,b s); 12.42 (1H,b s).
The solution of 8-(nitro(N methyl-4,2-pyrrole)carbonylimino) (1,3,5-naphthalentrisulfonic acid trisodium salt)(1.803 g = 3 mmols) in water (120 ml) and 1NHCl (3 ml) was reduced over a Pd catalyst (10% on carbon g 800) under H₂ pressure (50 p.s.i.) for 4 h.
The catalyst was filtered and the resulting solution was concentrated in vacuum to dryness, affording 1.8 g of the title compound.
I.R. (KBr) cm⁻¹: 3440 b, 1640, 1520, 1190, 1030
N.M.R. (DMSO-d6):δ3.9 (3H,s); 7.11 (1H,d); 7.29 (1H,d); 8.04 (2H,m); 8.6 (1H,d); 9.88 (1H,d); 10.04 (3H, b s); 12.39 (1H, b s).
To a solution of 8-amino, 1,3,5-naphthalentrisulfonic acid trisodium salt (1.347 g = 3 mmols) in water (45 ml), sodium acetate (0.492 g = 6 mM) was added under stirring. The solution was cooled at 5°C with an ice bath, then a solution of (4-nitro-N methyl-2-pyrrole)carbonyl chloride (0.943 = 5 mmols) in dioxane (45 ml) was added dropwise in 1 h. The mixture was stirred 3 h at 5°C, acidified and pH 4 with 1N HCl and evaporated under vacuum to dryness.
The residue was treated with ethylacetate (300 ml), stirred for 1 hour and filtered, to obtain g 1.7 of the title compound.
I.R.(KBr) cm⁻¹: 3440 b, 1650, 1530, 1305, 1200, 1030.
N.M.R.(DMSO-d6):δ3.96 (3H,s); 7.84 (1H,d); 8.06 (2H,m); 8.15 (1H,d); 8.63 (1H,d); 9.4 (1H,d); 12.55 (1H, bs).
To a solution of 7-(amino-N-methyl-4,2-pyrrolecarbonylimino(N-methyl-4,2-pyrrole)carbonylimino))(1,3-naphthalendisulfonic acid dipotassium salt) hydrochloride (160 mg, 0.24 mmols) in water (15 ml) and dioxane (10 ml), potassium acetate (50 mg, 0.51 mmols) was added under stirring. A 20% solution of phosgene in toluene (0.5 ml, ≃ 1 mmol), diluted with dioxane (2 ml), was added dropwise in half hr at room temperature. The mixture was stirred 1 hr. at room temperature.
The solvents were evaporated undervacuum, the residue was cromatographed on a silica gel column with methylene chloride:methanol: water 40:60:6 as eluent, affording 90 mg of the title compound.
I.R.(KBr) cm⁻¹: 3450 (b); 1650; 1580; 1530; 1190; 1030
N.M.R.(DMSO-d6): δ 3.84 (3H,s); 3.87 (3H,s); 6.80 (1H,d); 7.05 (1H,d); 7.18 (1H,d); 7.33 (1H,d); 7.86 (2H,m); 8.00 (1H,d); 8.16 (1H,bs); 8.21 (1H,d); 8.95 (1H, bs); 9.86 (1H, bs); 10.21 (1H, bs).
U.V. (H₂O)mm:
316.8 (371), 248.95 (444)
F.A.B. M.J.: m/z : 1273 (M⁺₊H); 1311 (M⁺₊K)
By analogous procedure the following compounds can be obtained:
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(1-naphthalensulfonic acid)disodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2-naphthalensulfonic acid) disodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrole-carbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(3-naphthalensulfonic acid) disodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(4-naphthalensulfonic acid) disodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,3-naphthalendisulfonic acid) tetrasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,4-naphthalendisulfonic acid) tetrasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,5-naphthalendisulfonic acid) tetrasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,5-naphthalendisulfonic acid) tetrasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(3,5-naphthalendisulfonic salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,6-naphthalendisulfonic acid) tetrasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,6-naphthamendisulfonic acid) tetrasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(3,6-naphthalendisulfonic acid) tetrasodium salt;
7-7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,3,5-naphthalentrisulfonic acid) hexasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,4,6-naphthalentrisulfonic acid) hexasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(1,3,6-naphthalentrisulfonic acid) hexasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrole-carbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,4,6-naphthalentrisulfonic acid) hexasodium salt;
7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2,3,5-naphthalentrisulfonic acid) hexasodium salt;
2,2'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2-deoxy-D-glucose-6-sulfate) disodium salt;
2,2'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(2-deoxy-D-glucose-6-phosphate) disodium salt;
5,5'-(carbonyl-bis(imino-N-methyl-4,2-pyrrocarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(8-quinolinesulfonic acid) disodium salt;
5,5'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(6-quinolinesulfonic acid) disodium salt;
8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolcarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(5,7-quinolinedisulfonic acid) tetrasodium salt; and
5,5'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino (N-methyl-4,2-pyrrole)carbonylimino))bis(6,8-quinolinedisulfonic acid) tetrasodium salt.
A solution of 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis (1,3,5-naphthalentrisulfonic acid)hexasodium salt (400 mg) in water (10 ml), is chromatographed on an Amberlite 1R-120(H) column (20 ml), with water as eluent.
The solution is evaporated to dryness in vacuum, affording 0,3 g of the title compound.
A injectable pharmaceutical preparation can be manufactured by dissolving 40 g of 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrole-carbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino)) bis(1,3,5-naphthalentrisulfonic acid)hexasodium salt in water for injection (1000 ml) and sealing ampoules of 1-10 ml.
Claims (11)
- A process for the preparation of a compound of formula (I): wherein each of m and n, being the same, is an integer of 1 to 3; W is oxygen or sulphur; each of the B groups, which are the same, isa) a phenyl or naphthyl group substituted by one or more acid groups;b) a saturated or unsaturated, heteromonocyclic or heterobicyclic ring, containing one or more heteroatoms chosen from nitrogen, oxygen and sulphur, substituted by one or more acid groups;c) a 2-deoxy-D-glucose group substituted by one or more acid groups; ord) a -CH₂(CHA)rCH₂A group, wherein each A group, being the same or different, is an acid group and r is 0, 1 or 2; and wherein each of the above acid groups is independently chosen from sulfonic, sulfuric, sulfamic, sulfinic, phosphoric, phosphonic, phosphamic and carboxylic acid groups; and the pharmaceutically acceptable salts thereof, which process comprises reaching a compound of formula (II) wherein n and B are as defined above, or a salt thereof, with a compound of formula (III) wherein W is as defined above, and each of the X groups, which may be the same or different, is a good leaving group, and if desired, salifying a compound of formula (I) thus obtained; and/or if desired, obtaining a free compound of formula (I) from a salt thereof.
- A process according to claim 1, wherein each of m and n, being the same, is 2; W is oxygen; each of the B groups, which are the same, is a') a phenyl or naphthyl group substituted by 1 to 3 acid groups; b') a tetrahydropyranyl or tetrahydrofuranyl ring substituted by 1 to 3 acid groups; or c') a 2-deoxy-D-glucose group substituted by 1 to 3 acid groups; and the pharmaceutically acceptable salts thereof.
- A process according to claim 1 wherein the compound prepared is selected from the group consisting of 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylamino))bis(1,3-naphthalendisulfonic acid); 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(3,5-naphthalendisulfonic acid); 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,5-naphthalendisulfonic acid); 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,4-naphthalendi-sulfonic acid); 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(1,6-naphthalendi-sulfonic acid); 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,4,6-naphthalentri-sulfonic acid); 8,8'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(1,3,6-napthalentri-sulfonic acid); 8,8'(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2,3,5-naphthalen-sulfonic acid); 2,2'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2-deoxy-D-glucose-6-sulphate); and 2,2'(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(2-deoxy-D-glucose-6-phosphate); and the pharmaceutically acceptable salts thereof.
- A process according to claim 3 wherein said salt is the sodium or the potassium salt.
- A process according to claim 1 wherein the compound prepared is 7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(1,3-naphthalendisulfonic acid)tetrapotassium salt.
- A process for preparing a pharmaceutical composition which comprises mixing together a pharmaceutically acceptable carrier and/or diluent and, as an active principle, a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 5.
- Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 5 in the preparation of a medicament for use in the treatment of angiogenesis.
- Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 5 in the preparation of a medicament for prophylactic and/or therapeutic use in a disease state in which TNFα plays a detrimental role.
- A compound of formula (II) wherein n and B are as defined in claim 1 or 2, or a salt thereof, with the proviso that B is not a -CH₂(CHA)rCH₂A group as defined in claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909000644A GB9000644D0 (en) | 1990-01-11 | 1990-01-11 | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| GB9000644 | 1990-01-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1006455B true HK1006455B (en) | 1999-02-26 |
| HK1006455A1 HK1006455A1 (en) | 1999-02-26 |
Family
ID=10669147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK98105643A HK1006455A1 (en) | 1990-01-11 | 1998-06-18 | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US5260329A (en) |
| EP (1) | EP0462258B1 (en) |
| JP (1) | JP3121343B2 (en) |
| KR (1) | KR0176258B1 (en) |
| CN (1) | CN1032750C (en) |
| AT (1) | ATE131810T1 (en) |
| AU (1) | AU647446B2 (en) |
| BG (1) | BG60534B2 (en) |
| CA (1) | CA2050331C (en) |
| CZ (1) | CZ285251B6 (en) |
| DE (1) | DE69115570T2 (en) |
| DK (1) | DK0462258T3 (en) |
| ES (1) | ES2084153T3 (en) |
| FI (1) | FI99011C (en) |
| GB (1) | GB9000644D0 (en) |
| GR (1) | GR3018767T3 (en) |
| HK (1) | HK1006455A1 (en) |
| HR (1) | HRP930311B1 (en) |
| HU (2) | HUT61280A (en) |
| IE (1) | IE69462B1 (en) |
| IL (1) | IL96875A (en) |
| MX (1) | MX9203119A (en) |
| MY (1) | MY107890A (en) |
| NO (1) | NO176274C (en) |
| NZ (1) | NZ236707A (en) |
| PT (1) | PT96455B (en) |
| RU (1) | RU2078079C1 (en) |
| SI (1) | SI9110025B (en) |
| SK (1) | SK280190B6 (en) |
| UA (1) | UA32513A (en) |
| WO (1) | WO1991010649A1 (en) |
| YU (1) | YU48548B (en) |
| ZA (1) | ZA91177B (en) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| AU1224392A (en) * | 1991-02-06 | 1992-09-07 | Synphar Laboratories, Inc. | Oligopeptide antiretroviral agents |
| GB2261661A (en) * | 1991-11-21 | 1993-05-26 | Erba Carlo Spa | Derivatives of poly-4-amino-2-carboxy-1-methyl pyrroles |
| GB9216962D0 (en) * | 1992-08-11 | 1992-09-23 | Erba Carlo Spa | Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives |
| GB9225475D0 (en) * | 1992-12-05 | 1993-01-27 | Imp Cancer Res Tech | Compounds to combat angiogenesis |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| GB9304589D0 (en) * | 1993-03-05 | 1993-04-21 | Erba Carlo Spa | Biologically active ureido derivatives useful as antimetastic agents |
| GB9307948D0 (en) * | 1993-04-16 | 1993-06-02 | Erba Carlo Spa | Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease |
| DE4320157A1 (en) * | 1993-06-18 | 1994-12-22 | Bayer Ag | Use of 1,2,4-dithiazolium salts as chemotherapeutic agents |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
| GB9504065D0 (en) * | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Poly-pyrrolecarboxamidonaphthalenic acid derivatives |
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| GB2310207A (en) * | 1996-02-15 | 1997-08-20 | Pharmacia Spa | Antiviral ureido derivatives of substituted heterocyclic compounds |
| ES2253787T3 (en) * | 1996-11-05 | 2006-06-01 | The Children's Medical Center Corporation | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS THAT INCLUDE TALIDOMIDE AND AN NSAID. |
| GB9713733D0 (en) * | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Poly-branched polycarboxamido compounds |
| GB9713732D0 (en) * | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Substituted triazinic compounds |
| WO1999027939A1 (en) * | 1997-12-04 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation |
| NZ505844A (en) * | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| GB0015447D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents |
| CA2430669C (en) | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| PL209822B1 (en) * | 2001-04-27 | 2011-10-31 | Kirin Pharma Kk | Quinoline derivative having azolyl group and quinazoline derivative |
| CA2450628A1 (en) * | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Benzothiophene compounds having antiinfective activity |
| AU2002323063B2 (en) * | 2001-08-06 | 2007-11-08 | Entremed, Inc. | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| NZ532062A (en) * | 2001-10-01 | 2006-09-29 | Univ Virginia | 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses |
| EP1471054B1 (en) * | 2002-01-11 | 2009-07-01 | Daiichi Sankyo Company, Limited | Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| KR20110136901A (en) | 2004-02-24 | 2011-12-21 | 상꾜 가부시키가이샤 | Amino alcohol compounds |
| WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| WO2006023272A1 (en) * | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
| SG155182A1 (en) * | 2004-08-02 | 2009-09-30 | Univ Virginia | 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity |
| WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| EP3381897A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer |
| US12152106B2 (en) | 2020-06-15 | 2024-11-26 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Electrically conducting polyamides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2785182A (en) * | 1954-04-19 | 1957-03-12 | American Cyanamid Co | Substituted pyrrolecarboxamidopyroles |
| US2785183A (en) * | 1954-04-19 | 1957-03-12 | American Cyanamid Co | N [4-aminopyrrolyl-2-carbonyl] amino acids |
| CA1308516C (en) * | 1987-07-06 | 1992-10-06 | J. William Lown | Oligopeptide anticancer and antiviral agents |
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
-
1990
- 1990-01-11 GB GB909000644A patent/GB9000644D0/en active Pending
-
1991
- 1991-01-03 IL IL9687591A patent/IL96875A/en not_active IP Right Cessation
- 1991-01-07 RU SU915001843A patent/RU2078079C1/en not_active IP Right Cessation
- 1991-01-07 HU HU912923A patent/HUT61280A/en unknown
- 1991-01-07 NZ NZ236707A patent/NZ236707A/en unknown
- 1991-01-07 WO PCT/EP1991/000014 patent/WO1991010649A1/en not_active Ceased
- 1991-01-07 ES ES91902204T patent/ES2084153T3/en not_active Expired - Lifetime
- 1991-01-07 AU AU70599/91A patent/AU647446B2/en not_active Ceased
- 1991-01-07 DE DE69115570T patent/DE69115570T2/en not_active Expired - Fee Related
- 1991-01-07 DK DK91902204.6T patent/DK0462258T3/en active
- 1991-01-07 EP EP91902204A patent/EP0462258B1/en not_active Expired - Lifetime
- 1991-01-07 CA CA002050331A patent/CA2050331C/en not_active Expired - Fee Related
- 1991-01-07 UA UA5001843A patent/UA32513A/en unknown
- 1991-01-07 AT AT91902204T patent/ATE131810T1/en not_active IP Right Cessation
- 1991-01-07 US US07/752,577 patent/US5260329A/en not_active Expired - Lifetime
- 1991-01-07 KR KR1019910701078A patent/KR0176258B1/en not_active Expired - Fee Related
- 1991-01-07 JP JP03502425A patent/JP3121343B2/en not_active Expired - Fee Related
- 1991-01-07 MX MX9203119A patent/MX9203119A/en unknown
- 1991-01-09 ZA ZA91177A patent/ZA91177B/en unknown
- 1991-01-10 CN CN91100140A patent/CN1032750C/en not_active Expired - Fee Related
- 1991-01-10 IE IE7491A patent/IE69462B1/en not_active IP Right Cessation
- 1991-01-10 PT PT96455A patent/PT96455B/en not_active IP Right Cessation
- 1991-01-10 SI SI9110025A patent/SI9110025B/en unknown
- 1991-01-10 YU YU2591A patent/YU48548B/en unknown
- 1991-01-10 MY MYPI91000036A patent/MY107890A/en unknown
- 1991-01-11 SK SK56-91A patent/SK280190B6/en unknown
- 1991-01-11 CZ CS9156A patent/CZ285251B6/en not_active IP Right Cessation
- 1991-09-09 FI FI914251A patent/FI99011C/en active
- 1991-09-10 NO NO913572A patent/NO176274C/en not_active IP Right Cessation
-
1993
- 1993-03-11 HR HRP-25/91A patent/HRP930311B1/en not_active IP Right Cessation
- 1993-05-25 US US08/066,583 patent/US5420296A/en not_active Expired - Fee Related
-
1994
- 1994-02-22 BG BG098517A patent/BG60534B2/en unknown
-
1995
- 1995-04-21 US US08/426,130 patent/US5593976A/en not_active Expired - Fee Related
- 1995-06-30 HU HU95P/P00701P patent/HU211237A9/en unknown
-
1996
- 1996-01-24 GR GR960400165T patent/GR3018767T3/en unknown
-
1998
- 1998-06-18 HK HK98105643A patent/HK1006455A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0462258B1 (en) | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds | |
| HK1006455B (en) | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds | |
| CA2030519C (en) | Acryloyl substituted pyrrole derivatives | |
| EP1100777B1 (en) | Sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents | |
| US5534539A (en) | Biologically active ureido derivatives useful as anit-metastic agenst | |
| EP1100778B1 (en) | Oxidised sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents | |
| GB2261661A (en) | Derivatives of poly-4-amino-2-carboxy-1-methyl pyrroles | |
| EP1084120B1 (en) | Cinnamoyl distamycin analogous derivatives, process for their preparation, and their use as antitumor agents | |
| US5596105A (en) | Therapeutically active naphthalenesulfonic pyrrolecarboxamido derivatives | |
| AU670194B2 (en) | Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease | |
| GB2289274A (en) | Angiogenesis inhibiting sialic acid derivatives and process for their preparation | |
| GB2260134A (en) | Derivatives of poly-5-amino-3-carboxy-1-methyl compounds |